◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Rohto Pharmaceutical Co.,Ltd. (4527) EPS 2022–2026

Name: Rohto Pharmaceutical Co.,Ltd. (4527) eps history 2022-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-11

Rohto Pharmaceutical Co.,Ltd. annual earnings per share (EPS) for fiscal 2026 was JPY 145.29, an increase of 7.8% from JPY 134.72 in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

4527 Annual EPS

EPS (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Diluted EPS	JPY 145M	JPY 135M	JPY 135M	JPY 115M	—

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

4527 Quarterly EPS

EPS (quarterly)	2026-06-30	2025-06-30
Diluted EPS	JPY 46M	JPY 52M

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EPS at Comparable Companies

4452 EPS — Kao Corporation
8113 EPS — Unicharm Corporation
4911 EPS — Shiseido Company, Limited
4912 EPS — Lion Corporation
4967 EPS — Kobayashi Pharmaceutical Co., Ltd.
8283 EPS — Paltac Corporation

More 4527 metrics: Revenue · Gross Profit · Operating Income · Net Income · Free Cash Flow

All 4527 financial statements → Interactive 4527 charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.